Invasive aspergillosis in primary immunodeficiencies

References

• Segal BH, Holland SM. Primary phagocytic disorders of childhood. Pediatr Clin North Am 2000; 47: 1311–1338
   Google Scholar
• Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) 2000; 79: 170–200
   PubMed Web of Science ®Google Scholar
• Babior BM. NADPH oxidase: an update. Blood 1999; 93: 1464–1476
   PubMed Web of Science ®Google Scholar
• Thrasher AJ, Keep NH, Wientjes F, Segal AW. Chronic granulomatous disease. Biochim Biophys Acta 1994; 1227: 1–24
   PubMed Web of Science ®Google Scholar
• Abo A, Pick E, Hall A, et al. Activation of the NADPH oxidase involves the small GTP-binding protein p21rac1. Nature 1991; 353: 668–670
   PubMed Web of Science ®Google Scholar
• Knaus UG, Heyworth PG, Evans T, Curnutte JT, Bokoch GM. Regulation of phagocyte oxygen radical production by the GTP-binding protein Rac 2. Science 1991; 254: 1512–1515
   PubMed Web of Science ®Google Scholar
• Reeves EP, Lu H, Jacobs HL, et al. Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature 2002; 416: 291–297
   PubMed Web of Science ®Google Scholar
• Tkalcevic J, Novelli M, Phylactides M, et al. Impaired immunity and enhanced resistance to endotoxin in the absence of neutrophil elastase and cathepsin G. Immunity 2000; 12: 201–210
   PubMed Web of Science ®Google Scholar
• Rosen-Wolff A, Soldan W, Heyne K, et al. Increased susceptibility of a carrier of X-linked chronic granulomatous disease (CGD) to Aspergillus fumigatus infection associated with age- related skewing of lyonization. Ann Hematol 2001; 80: 113–115
   PubMed Web of Science ®Google Scholar
• Curnutte JT, Hopkins PJ, Kuhl W, Beutler E. Studying X inactivation. Lancet 1992; 339: 749
   PubMed Web of Science ®Google Scholar
• Vowells SJ, Fleisher TA, Malech HL. Testing for chronic granulomatous disease. Lancet 1996; 347: 1048–1049
   PubMed Web of Science ®Google Scholar
• Liese JG, Jendrossek V, Jansson A, et al. Chronic granulomatous disease in adults. Lancet 1996; 347: 220–223
   PubMed Web of Science ®Google Scholar
• Vowells SJ, Sekhsaria S, Malech HL, Shalit M, Fleisher TA. Flow cytometric analysis of the granulocyte respiratory burst: a comparison study of fluorescent probes. J Immunol Methods 1995; 178: 89–97
   PubMed Web of Science ®Google Scholar
• Gallin JI, Buescher ES, Seligmann BE, et al. NIH conference. Recent advances in chronic granulomatous disease. Ann Intern Med 1983; 99: 657–674
   PubMed Web of Science ®Google Scholar
• Tauber AI, Borregaard N, Simons E, Wright J. Chronic granulomatous disease: a syndrome of phagocyte oxidase deficiencies. Medicine (Baltimore) 1983; 62: 286–309
   PubMed Web of Science ®Google Scholar
• Winkelstein JA, Marino MC, Johnston RB, Jr, et al. Chronic granulomatous disease: report on a national registry of 368 patients. Medicine (Baltimore) 2000; 79: 155–169
   PubMed Web of Science ®Google Scholar
• Cohen MS, Isturiz RE, Malech HL, et al. Fungal infection in chronic granulomatous disease. The importance of the phagocyte in defense against fungi. Am J Med 1981; 71: 59–66
   PubMed Web of Science ®Google Scholar
• Mouy R, Veber F, Blanche S, et al. Long-term itraconazole prophylaxis against Aspergillus infections in thirty-two patients with chronic granulomatous disease. J Pediatr 1994; 125((6 Pt 1))998–1003
   Google Scholar
• Segal BH, DeCarlo ES, Kwon-Chung KJ, et al. Aspergillus, nidulans infection in chronic granulomatous disease. Medicine (Baltimore) 1998; 77: 345–354
   PubMed Web of Science ®Google Scholar
• Liese J, Kloos S, Jendrossek V, et al. Long-term follow-up and outcome of 39 patients with chronic granulomatous disease. J Pediatr 2000; 137: 687–693
   PubMed Web of Science ®Google Scholar
• Mouy R, Ropert JC, Donadieu J, et al. Chronic septic granulomatosis revealed by neonatal pulmonary aspergillosis. Arch Pediatr 1995; 2: 861–864
   Google Scholar
• Groll AH, Jaeger G, Allendorf A, et al. Invasive pulmonary aspergillosis in a critically ill neonate: case report and review of invasive aspergillosis during the first 3 months of life. Clin Infect Dis 1998; 27: 437–452
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Lewis RE, May GS, Osherov N, Rinaldi MG. Aspergillus nidulans is frequently resistant to amphotericin B. Mycoses 2002; 45: 406–407
   PubMed Web of Science ®Google Scholar
• Casale TB, Macher AM, Fauci AS. Concomitant pulmonary aspergillosis and nocardiosis in a patient with chronic granulomatous disease of childhood. South Med J 1984; 77: 274–275
   PubMed Web of Science ®Google Scholar
• Conrad DJ, Warnock M, Blanc P, Cowan M, Golden JA. Microgranulomatous aspergillosis after shoveling wood chips: report of a fatal outcome in a patient with chronic granulomatous disease. Am J Ind Med 1992; 22: 411–418
   PubMed Web of Science ®Google Scholar
• Chusid MJ, Sty JR, Wells RG. Pulmonary aspergillosis appearing as chronic nodular disease in chronic granulomatous disease. Pediatr Radiol 1988; 18: 232–234
   PubMed Web of Science ®Google Scholar
• Hotchi M, Fujiwara M, Hata S, Nasu T. Chronic granulomatous disease associated with peculiar Aspergillus lesions. Patho-anatomical report based on two autopsy cases and a brief review of all autopsy cases reported in Japan. Virchows Arch A Pathol Anat Histol 1980; 387: 1–15
   PubMedGoogle Scholar
• Morgenstern DE, Gifford MA, Li LL, Doerschuk CM, Dinauer MC. Absence of respiratory burst in X-linked chronic granulomatous disease mice leads to abnormalities in both host defense and inflammatory response to Aspergillus fumigatus. J Exp Med 1997; 185: 207–218
   PubMed Web of Science ®Google Scholar
• Chatzipanagiotou S, Takou K, Perogamvros A. Cutaneous purulent aspergillosis in a young man with chronic granulomatous disease. Mycoses 1998; 41: 379–382
   Google Scholar
• Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997; 15: 139–147
   PubMed Web of Science ®Google Scholar
• Marr KA, Balajee SA, McLaughlin L, et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190: 641–649
   PubMed Web of Science ®Google Scholar
• Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97: 1604–1610
   PubMed Web of Science ®Google Scholar
• Maertens J, Van Eldere J, Verhaegen J, et al. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 2002; 186: 1297–1306
   PubMed Web of Science ®Google Scholar
• Walsh, TJ, Schaufele, RL, Sein, T, , et al. Reduced expression of galactomannan antigenemia in patients with invasive aspergillosis and chronic granulomatous disease or Job's syndrome. Infectious Disease Society of America 40th annual meeting. 2002; Chicago, IL. Abstract 345.
   Google Scholar
• Verweij PE, Weemaes CM, Curfs JH, Bretagne S, Meis JF. Failure to detect circulating Aspergillus markers in a patient with chronic granulomatous disease and invasive aspergillosis. J Clin Microbiol 2000; 38: 3900–3901
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new “gold standard”. Clin Infect Dis 2003; 37: 415–425
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–415
   PubMed Web of Science ®Google Scholar
• Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563–571
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis, and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21: 240–248
   PubMed Web of Science ®Google Scholar
• Segal, BH, Barnhart, LA, Anderson, VL, Malech, HL, Holland, SM. Posaconazole as salvage therapy in patients with chronic granulomatous disease (CGD) with invasive filamentous fungal infection. 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. September, 2003. Chicago, IL. Abstract M-1756.
   Google Scholar
• Maertens J, Boogaerts M. Caspofungin in the treatment of candidosis and aspergillosis. Int J Infect Dis 2003; 7: 94–101
   Google Scholar
• Kartsonis, N, Saah, A, Lipka, J, Taylor, A, Sable, C. Salvage therapy (Rx) with caspofungin (CAS) for invasive aspergillosis (IA): results from the CAS compassionate use (CU) study. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. September, 2003; Chicago, IL. Abstract M-981.
   Google Scholar
• Margolis DM, Melnick DA, Alling DW, Gallin JI. Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis 1990; 162: 723–726
   PubMed Web of Science ®Google Scholar
• Gallin JI, Alling DW, Malech HL, et al. Itraconazole prophylaxis for fungal infections in chronic granulomatous disease of childhood. N Engl J Med 2003; 348: 2416–2422
   PubMed Web of Science ®Google Scholar
• Gallin JI, Farber JM, Holland SM, Nutman TB. Interferon-gamma in the management of infectious diseases. Ann Intern Med 1995; 123: 216–224
   PubMed Web of Science ®Google Scholar
• Nathan CF, Horowitz CR, de la Harpe J, et al. Administration of recombinant interferon gamma to cancer patients enhances monocyte secretion of hydrogen peroxide. Proc Natl Acad Sci USA 1985; 82: 8686–8690
   PubMed Web of Science ®Google Scholar
• Nathan CF, Kaplan G, Levis WR, et al. Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. N Engl J Med 1986; 315: 6–15
   PubMed Web of Science ®Google Scholar
• Sechler JM, Malech HL, White CJ, Gallin JI. Recombinant human interferon-gamma reconstitutes defective phagocyte function in patients with chronic granulomatous disease of childhood. Proc Natl Acad Sci USA 1988; 85: 4874–4878
   PubMed Web of Science ®Google Scholar
• Ezekowitz RA, Orkin SH, Newburger PE. Recombinant interferon gamma augments phagocyte superoxide production and X-chronic granulomatous disease gene expression in X-linked variant chronic granulomatous disease. J Clin Invest 1987; 80: 1009–1016
   PubMed Web of Science ®Google Scholar
• Ezekowitz RA, Dinauer MC, Jaffe HS, Orkin SH, Newburger PE. Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma. N Engl J Med 1988; 319: 146–151
   PubMed Web of Science ®Google Scholar
• Rex JH, Bennett JE, Gallin JI, et al. In vivo interferon-gamma therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae. J Infect Dis 1991; 163: 849–852
   PubMed Web of Science ®Google Scholar
• The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991; 324: 509–516
   PubMed Web of Science ®Google Scholar
• Woodman RC, Erickson RW, Rae J, Jaffe HS, Curnutte JT. Prolonged recombinant interferon-gamma therapy in chronic granulomatous disease: evidence against enhanced neutrophil oxidase activity. Blood 1992; 79: 1558–1562
   PubMed Web of Science ®Google Scholar
• Muhlebach TJ, Gabay J, Nathan CF, et al. Treatment of patients with chronic granulomatous disease with recombinant human interferon-gamma does not improve neutrophil oxidative metabolism, cytochrome b558 content or levels of four anti- microbial proteins. Clin Exp Immunol 1992; 88: 203–206
   PubMed Web of Science ®Google Scholar
• Jackson SH, Miller GF, Segal BH, et al. IFN-gamma is effective in reducing infections in the mouse model of chronic granulomatous disease (CGD). J Interfer Cytokine Res 2001; 21: 567–573
   Google Scholar
• Schiff DE, Rae J, Martin TR, Davis BH, Curnutte JT. Increased phagocyte Fc gammaRI expression and improved Fc gamma- receptor-mediated phagocytosis after in vivo recombinant human interferon-gamma treatment of normal human subjects. Blood 1997; 90: 3187–3194
   PubMed Web of Science ®Google Scholar
• Ahlin A, Elinder G, Palmblad J. Dose-dependent enhancements by interferon-gamma on functional responses of neutrophils from chronic granulomatous disease patients. Blood 1997; 89: 3396–3401
   Google Scholar
• Bernhisel-Broadbent J, Camargo EE, Jaffe HS, Lederman HM. Recombinant human interferon-gamma as adjunct therapy for Aspergillus infection in a patient with chronic granulomatous disease. J Infect Dis 1991; 163: 908–911
   PubMed Web of Science ®Google Scholar
• Rex JH, Bennett JE, Gallin JI, Malech HL, Melnick DA. Normal and deficient neutrophils can cooperate to damage Aspergillus fumigatus hyphae. J Infect Dis 1990; 162: 523–528
   PubMed Web of Science ®Google Scholar
• Ohno Y, Gallin JI. Diffusion of extracellular hydrogen peroxide into intracellular compartments of human neutrophils. Studies utilizing the inactivation of myeloperoxidase by hydrogen peroxide and azide. J Biol Chem 1985; 260: 8438–8446
   PubMed Web of Science ®Google Scholar
• Buescher ES, Gallin JI. Leukocyte transfusions in chronic granulomatous disease: persistence of transfused leukocytes in sputum. N Engl J Med 1982; 307: 800–803
   Google Scholar
• Gallin JI, Buescher ES. Abnormal regulation of inflammatory skin responses in male patients with chronic granulomatous disease. Inflammation 1983; 7: 227–232
   PubMed Web of Science ®Google Scholar
• Emmendorffer A, Lohmann-Matthes ML, Roesler J. Kinetics of transfused neutrophils in peripheral blood and BAL fluid of a patient with variant X-linked chronic granulomatous disease. Eur J Haematol 1991; 47: 246–252
   PubMed Web of Science ®Google Scholar
• Wright DG, Robichaud KJ, Pizzo PA, Deisseroth AB. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N Engl J Med 1981; 304: 1185–1189
   PubMed Web of Science ®Google Scholar
• Calvino MC, Maldonado MS, Otheo E, et al. Bone marrow transplantation in chronic granulomatous disease. Eur J Pediatr 1996; 155: 877–879
   PubMed Web of Science ®Google Scholar
• Ho CM, Vowels MR, Lockwood L, Ziegler JB. Successful bone marrow transplantation in a child with X-linked chronic granulomatous disease. Bone Marrow Transplant 1996; 18: 213–215
   PubMed Web of Science ®Google Scholar
• Kamani N, August CS, Douglas SD, et al. Bone marrow transplantation in chronic granulomatous disease. J Pediatr 1984; 105: 42–46
   Google Scholar
• Kamani N, August CS, Campbell DE, Hassan NF, Douglas SD. Marrow transplantation in chronic granulomatous disease: an update, with 6-year follow-up. J Pediatr 1988; 113: 697–700
   Google Scholar
• Seger RA, Ezekowitz RA. Treatment of chronic granulomatous disease. Immunodeficiency 1994; 5: 113–130
   Google Scholar
• Horwitz ME, Barrett AJ, Brown MR, et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med 2001; 344: 881–888
   PubMed Web of Science ®Google Scholar
• Watanabe C, Yajima S, Taguchi T, et al. Successful unrelated bone marrow transplantation for a patient with chronic granulomatous disease and associated resistant pneumonitis and Aspergillus osteomyelitis. Bone Marrow Transplant 2001; 28: 83–87
   Google Scholar
• Ozsahin H, von Planta M, Muller I, et al. Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B. Blood 1998; 92: 2719–2724
   PubMed Web of Science ®Google Scholar
• Malech HL, Bauer TR, Jr, Hickstein DD. Prospects for gene therapy of neutrophil defects. Semin Hematol 1997; 34: 355–361
   PubMed Web of Science ®Google Scholar
• Chanock SJ, Faust LR, Barrett D, et al. O2- production by B lymphocytes lacking the respiratory burst oxidase subunit p47phox after transfection with an expression vector containing a p47phox cDNA. Proc Natl Acad Sci USA 1992; 89: 10174–10177
   Google Scholar
• Maly FE, Schuerer-Maly CC, Quilliam L, et al. Restitution of superoxide generation in autosomal cytochrome-negative chronic granulomatous disease (A22(0) CGD)-derived B lymphocyte cell lines by transfection with p22phox cDNA. J Exp Med 1993; 178: 2047–2053
   Google Scholar
• Porter CD, Parkar MH, Verhoeven AJ, et al. p22-phox-deficient chronic granulomatous disease: reconstitution by retrovirus-mediated expression and identification of a biosynthetic intermediate of gp91-phox. Blood 1994; 84: 2767–2775
   Google Scholar
• Porter CD, Parkar MH, Levinsky RJ, Collins MK, Kinnon C. X-linked chronic granulomatous disease: correction of NADPH oxidase defect by retrovirus-mediated expression of gp91-phox. Blood 1993; 82: 2196–2202
   Google Scholar
• Thrasher A, Chetty M, Casimir C, Segal AW. Restoration of superoxide generation to a chronic granulomatous disease- derived B-cell line by retrovirus mediated gene transfer. Blood 1992; 80: 1125–1129
   PubMed Web of Science ®Google Scholar
• Volpp BD, Lin Y. In vitro molecular reconstitution of the respiratory burst in B lymphoblasts from p47-phox-deficient chronic granulomatous disease. J Clin Invest 1993; 91: 201–207
   Google Scholar
• Thrasher AJ, Casimir CM, Kinnon C, et al. Gene transfer to primary chronic granulomatous disease monocytes. Lancet 1995; 346: 92–93
   Google Scholar
• Ding C, Kume A, Bjorgvinsdottir H, et al. High-level reconstitution of respiratory burst activity in a human X- linked chronic granulomatous disease (X-CGD) cell line and correction of murine X-CGD bone marrow cells by retroviral-mediated gene transfer of human gp91phox. Blood 1996; 88: 1834–1840
   PubMed Web of Science ®Google Scholar
• Porter CD, Parkar MH, Collins MK, Levinsky RJ, Kinnon C. Efficient retroviral transduction of human bone marrow progenitor and long-term culture-initiating cells: partial reconstitution of cells from patients with X-linked chronic granulomatous disease by gp91-phox expression. Blood 1996; 87: 3722–3730
   PubMed Web of Science ®Google Scholar
• Li F, Linton GF, Sekhsaria S, et al. CD34+ peripheral blood progenitors as a target for genetic correction of the two flavocytochrome b558 defective forms of chronic granulomatous disease. Blood 1994; 84: 53–58
   PubMed Web of Science ®Google Scholar
• Weil WM, Linton GF, Whiting-Theobald N, et al. Genetic correction of p67phox deficient chronic granulomatous disease using peripheral blood progenitor cells as a target for retrovirus mediated gene transfer. Blood 1997; 89: 1754–1761
   PubMed Web of Science ®Google Scholar
• Sekhsaria S, Gallin JI, Linton GF, et al. Peripheral blood progenitors as a target for genetic correction of p47phox-deficient chronic granulomatous disease. Proc Natl Acad Sci USA 1993; 90: 7446–7450
   PubMed Web of Science ®Google Scholar
• Bjorgvinsdottir H, Ding C, Pech N, et al. Retroviral-mediated gene transfer of gp91phox into bone marrow cells rescues defect in host defense against Aspergillus fumigatus in murine X-linked chronic granulomatous disease. Blood 1997; 89: 41–48
   PubMed Web of Science ®Google Scholar
• Mardiney M, 3rd, Jackson SH, Spratt SK, et al. Enhanced host defense after gene transfer in the murine p47phox- deficient model of chronic granulomatous disease. Blood 1997; 89: 2268–2275
   PubMed Web of Science ®Google Scholar
• Malech HL, Maples PB, Whiting-Theobald N, et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci USA 1997; 94: 12133–12138
   PubMed Web of Science ®Google Scholar
• Dinauer MC, Gifford MA, Pech N, Li LL, Emshwiller P. Variable correction of host defense following gene transfer and bone marrow transplantation in murine X-linked chronic granulomatous disease. Blood 2001; 97: 3738–3745
   PubMed Web of Science ®Google Scholar
• Grimbacher B, Holland SM, Gallin JI, et al. Hyper-IgE syndrome with recurrent infections--an autosomal dominant multisystem disorder. N Engl J Med 1999; 340: 692–702
   PubMed Web of Science ®Google Scholar
• Grimbacher B, Schaffer AA, Holland SM, et al. Genetic linkage of hyper-IgE syndrome to chromosome 4. Am J Hum Genet 1999; 65: 735–744
   PubMed Web of Science ®Google Scholar
• Donabedian H, Gallin JI. The hyperimmunoglobulin E recurrent-infection (Job's) syndrome. A review of the NIH experience and the literature. Medicine (Baltimore) 1983; 62: 195–208
   PubMed Web of Science ®Google Scholar
• Santambrogio L, Nosotti M, Pavoni G, Harte M, Pietogrande MC. Pneumatocele complicated by fungal lung abscess in Job's syndrome. Successful lobectomy with the aid of videothoracoscopy. Scand Cardiovasc J 1997; 31: 177–179
   PubMed Web of Science ®Google Scholar
• Hall RA, Salhany KE, Lebel E, Bavaria JE, Kaiser LR. Fungal pulmonary abscess in an adult secondary to hyperimmunoglobulin E (Job's) syndrome. Ann Thorac Surg 1995; 59: 759–761
   Google Scholar
• Lekstrom-Himes JA, Gallin JI. Immunodeficiency diseases caused by defects in phagocytes. N Engl J Med 2000; 343: 1703–1714
   PubMed Web of Science ®Google Scholar
• Welte K, Dale D. Pathophysiology and treatment of severe chronic neutropenia. Ann Hematol 1996; 72: 158–165
   PubMedGoogle Scholar
• Wright DG, Dale DC, Fauci AS, Wolff SM. Human cyclic neutropenia: clinical review and long-term follow-up of patients. Medicine (Baltimore) 1981; 60: 1–13
   PubMed Web of Science ®Google Scholar
• Nakahira M, Matsumoto S, Mukushita N, Nakatani H. Primary aspergillosis of the larynz assocaited with CD4+ T lymphocytopenia. J Laryngol Otol 2002; 116: 304–306
   PubMed Web of Science ®Google Scholar
• Saiki O, Ogawa H, Ikeda T, et al. Acquired T cell specific deficiency other than acquired immunodeficiency syndrome (AIDS). Intern Med 1992; 31: 11–16
   Google Scholar
• Viallard JF, Monlun E, Neau D, et al. Aspergillosis of the muscle in a woman with sarcoidosis and CD4+ lymphocytopenia. Clin Infect Dis 1995; 21: 1345–1346
   PubMedGoogle Scholar
• Buckley RH. Primary immunodeficiency diseases due to defects in lymphocytes. N Engl J Med 2000; 343: 1313–1324
   PubMed Web of Science ®Google Scholar
• Muller FM, Trusen A, Weig M. Clinical manifestations and diagnosis of invasive aspergillosis in immunocompromised children. Eur J Pediatr 2002; 161: 563–574
   PubMed Web of Science ®Google Scholar
• Yoshihara T, Morimoto A, Nakauchi S, et al. Successful transplantation of haploidentical CD34+ selected bone marrow cells for an infantile case of severe combined immunodeficiency with aspergillus pneumonia. Pediatr Hematol Oncol 2002; 19: 439–443
   PubMed Web of Science ®Google Scholar
• Marcinkowski M, Bauer K, Stoltenburg-Didinger G, Vogel M, Versmold H. Fatal aspergillosis with brain abscesses in a neonate with DiGeorge syndrome. Pediatr Infect Dis J 2000; 19: 1214–1216
   PubMed Web of Science ®Google Scholar
• Romani L. Immunity to fungal infections. Nat Rev Immunol 2004; 4: 1–23
   PubMed Web of Science ®Google Scholar
• Stevens DA. Vaccinate against aspergillosis! A call to arms of the immune system. Clin Infect Dis 2004; 38: 1131–1136
   PubMed Web of Science ®Google Scholar
• McKee DH, Cooper PN, Denning DW. Invasive aspergillosis in a patient with MELAS syndrome. J Neurol Neurosurg Psychiatry 2000; 68: 765–767
   PubMed Web of Science ®Google Scholar
• Warris A, Verweij PE, Barton R, et al. Invasive aspergillosis in two patients with Pearson syndrome. Pediatr Infect Dis J 1999; 18: 739–741
   PubMed Web of Science ®Google Scholar